Restricted accessResearch articleFirst published online 2022-9
The association between N -methyl- d -aspartate receptor availability and glutamate levels: A multi-modal PET-MR brain imaging study in first-episode psychosis and healthy controls
Evidence from post-mortem studies and in vivo imaging studies suggests there may be reduced N-methyl-d-aspartate receptor (NMDAR) levels in the hippocampus in patients with schizophrenia. Other studies have reported increased glutamate in striatum in schizophrenia patients. It has been hypothesised that NMDAR hypofunction leads to the disinhibition of glutamatergic signalling; however, this has not been tested in vivo.
Methods:
In this study, we investigated the relationship between hippocampal NMDAR and striatal glutamate using simultaneous positron emission tomography-magnetic resonance (PET-MR) imaging. We recruited 40 volunteers to this cross-sectional study; 21 patients with schizophrenia, all in their first episode of illness, and 19 healthy controls. We measured hippocampal NMDAR availability using the PET ligand [18F]GE179. This was indexed relative to whole brain as the distribution volume ratio (DVR). Striatal glutamatergic indices (glutamate and Glx) were acquired simultaneously, using combined PET-MR proton magnetic resonance spectroscopy (1H-MRS).
Results:
A total of 33 individuals (15 healthy controls, 18 patients) were included in the analyses (mean (SD) age of controls, 27.31 (4.68) years; mean (SD) age of patients, 24.75 (4.33), 27 male and 6 female). We found an inverse relationship between hippocampal DVR and striatal glutamate levels in people with first-episode psychosis (rho = −0.74, p < 0.001) but not in healthy controls (rho = −0.22, p = 0.44).
Conclusion:
This study show that lower relative NMDAR availability in the hippocampus may drive increased striatal glutamate levels in patients with schizophrenia. Further work is required to determine whether these findings may yield new targets for drug development in schizophrenia.
AdamsRABushvDZhengF, et al. (2020) Impaired theta phase coupling underlies frontotemporal dysconnectivity in schizophrenia. Brain143(4): 1261–1277.
2.
AllenPHirdEJOrlovN, et al. (2021) Adverse clinical outcomes in people at clinical high-risk for psychosis related to altered interactions between hippocampal activity and glutamatergic function. Translational Psychiatry11(1): 1–9.
3.
BasselinMChangLBellJM, et al. (2006) Chronic lithium chloride administration attenuates brain NMDA receptor-initiated signaling via arachidonic acid in unanesthetized rats. Neuropsychopharmacology31(8): 1659–1674.
4.
BeckKMcCutcheonRStephensonL, et al. (2019) Prevalence of treatment-resistant psychoses in the community: A naturalistic study. Journal of Psychopharmacology33(10): 1248–1253.
5.
BeckKHindleyGBorganF, et al. (2020) Association of ketamine with psychiatric symptoms and implications for its therapeutic use and for understanding schizophrenia: A systematic review and meta-analysis. JAMA Network Open3(5): e204693.
6.
BeckKArumuhamAVeroneseM, et al. (2021) N-methyl-D-aspartate receptor availability in first-episode psychosis: A PET-MR brain imaging study. Translational Psychiatry11(1): 1–8.
7.
BelforteJEZsirosVSklarER, et al. (2010) Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes. Nature Neuroscience13(1): 76–83.
8.
BeneytoMKristiansenLVOni-OrisanA, et al. (2007) Abnormal glutamate receptor expression in the medial temporal lobe in schizophrenia and mood disorders. Neuropsychopharmacology32(9): 1888–1902.
9.
BorganFLaurikainenHVeroneseM, et al. (2019a) In vivo availability of cannabinoid 1 receptor levels in patients with first-episode psychosis. JAMA Psychiatry76(10): 1074–1084.
10.
BorganFO’DalyOVeroneseM, et al. (2019b) The neural and molecular basis of working memory function in psychosis: A multimodal PET-fMRI study. Molecular Psychiatry26: 4464–4474.
11.
BreierAAdlerCMWeisenfeldN, et al. (1998) Effects of NMDA antagonism on striatal dopamine release in healthy subjects: Application of a novel PET approach. Synapse29(2): 142–147.
12.
BreitbordeNJSrihariVHWoodsSW (2009) Review of the operational definition for first-episode psychosis. Early Intervention in Psychiatry3(4): 259–265.
13.
ChowdhuryGGMIBeharKLChoW, et al. (2012) 1H-[13C]-nuclear magnetic resonance spectroscopy measures of ketamine’s effect on amino acid neurotransmitter metabolism.Biological Psychiatry71(11): 1022–1025.
14.
De La Fuente-SandovalCLeón-OrtizPAzcárragaM, et al. (2013) Glutamate levels in the associative striatum before and after 4 weeks of antipsychotic treatment in first-episode psychosis: A longitudinal proton magnetic resonance spectroscopy study. JAMA Psychiatry70(10): 1057–1066.
15.
FirstMBSpitzerRLGibbonM, et al. (2002) Structured Clinical Interview for DSM-IV-TR Axis I Disorders. New York: New York State Psychiatric Institute.
16.
GoffDHillMBarchD (2011) The treatment of cognitive impairment in schizophrenia. Pharmacology Biochemistry and Behavior99(2): 245–253.
17.
GoodroeSCStarnesJBrownTI (2018). The complex nature of hippocampal-striatal interactions in spatial navigation. Frontiers in Human Neuroscience12: 250.
18.
GraceAA (2012) Dopamine system dysregulation by the hippocampus: Implications for the pathophysiology and treatment of schizophrenia. Neuropharmacology62(3): 1342–1348.
19.
GraceAAGomesFV (2019) The circuitry of dopamine system regulation and its disruption in schizophrenia: Insights into treatment and prevention. Schizophrenia Bulletin45(1): 148–157.
20.
HowesODBhatnagarAGaughranFP, et al. (2004) A prospective study of impairment in glucose control caused by clozapine without changes in insulin resistance. The American Journal of Psychiatry161(2): 361–363.
21.
HowesODMcCutcheonRAgidO, et al. (2017) Treatment-resistant schizophrenia: Treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. American Journal of Psychiatry174(3): 216–229.
22.
IltisIKoskiDMEberlyLE, et al. (2009) Neurochemical changes in the rat prefrontal cortex following acute phencyclidine treatment: An in vivo localized 1 H MRS study. NMR in Biomedicine22(7): 737–744.
23.
JauharSVeroneseMNourMM, et al. (2019) Determinants of treatment response in first-episode psychosis: An 18F-DOPA PET study. Molecular Psychiatry24(10): 1502–1512.
24.
KaarSJNatesanSMcCutcheonR, et al. (2020) Antipsychotics: Mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology. Neuropharmacology172: 107704.
25.
KaySRFiszbeinAOplerLA (1987) The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin13(2): 261–276.
26.
KegelesLSAbi-DarghamAZea-PonceY, et al. (2000) Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: Implications for schizophrenia. Biological Psychiatry48(7): 627–640.
27.
KokkinouMAshokAHHowesOD (2017) The effects of ketamine on dopaminergic function: Meta-analysis and review of the implications for neuropsychiatric disorders. Molecular Psychiatry23(1): 59–69.
28.
KorotkovaTFuchsECPonomarenkoA, et al. (2010) NMDA receptor ablation on parvalbumin-positive interneurons impairs hippocampal synchrony, spatial representations, and working memory. Neuron68(3): 557–569.
LeuchtSSamaraMHeresS, et al. (2014) Dose equivalents for second-generation antipsychotics: The minimum effective dose method. Schizophrenia Bulletin40(2): 314–326.
31.
LiebermanJAGirgisRRBrucatoG, et al. (2018) Hippocampal dysfunction in the pathophysiology of schizophrenia: A selective review and hypothesis for early detection and intervention. Molecular Psychiatry23(8): 1764–1772.
32.
LodgeDJGraceAA (2011) Hippocampal dysregulation of dopamine system function and the pathophysiology of schizophrenia. Trends in Pharmacological Sciences32(9): 507–513
33.
LorrainDSBacceiCSBristowLJ, et al. (2003) Effects of ketamine and N-methyl-d-aspartate on glutamate and dopamine release in the rat prefrontal cortex: Modulation by a group II selective metabotropic glutamate receptor agonist LY379268.Neuroscience117(3): 697–706.
34.
McCutcheonRAAbi-DarghamAHowesOD (2019) Schizophrenia, dopamine and the striatum: From biology to symptoms. Trends in Neurosciences42(3): 205–220.
35.
McCutcheonRABrownKNourMM, et al. (2021) Dopaminergic organization of striatum is linked to cortical activity and brain expression of genes associated with psychiatric illness. Science Advances7(24): eabg1512.
36.
McCutcheonRAKrystalJHHowesOD (2020a) Dopamine and glutamate in schizophrenia: Biology, symptoms and treatment. World Psychiatry19(1): 15–33.
37.
McCutcheonRAMarquesTRHowesandOD (2020b) Schizophrenia – An overview. JAMA Psychiatry77(2): 1.
38.
McGinnityCJÅrstadEBeckandK, et al. (2018) Comment on ‘In Vivo [18F]GE-179 brain signal does not show NMDA-specific modulation with drug challenges in rodents and nonhuman primates’. ACS Chemical Neuroscience10(1): 768–772.
39.
McGinnityCJHammersARiaño BarrosDA, et al. (2014) Initial evaluation of 18F-GE-179, a putative PET Tracer for activated N-methyl D-aspartate receptors. Journal of Nuclear Medicine55(3): 423–430.
40.
McGinnityCJKoeppMJHammersA, et al. (2015) NMDA receptor binding in focal epilepsies. Journal of Neurology, Neurosurgery, and Psychiatry86(10): 1150–1157.
41.
MerrittKEgertonAKemptonMJ, et al. (2016) Nature of glutamate alterations in schizophrenia. JAMA Psychiatry73(7): 665.
42.
MerrittKMcGuirePKEgertonA, et al. (2021) Association of age, antipsychotic medication, and symptom severity in schizophrenia with proton magnetic resonance spectroscopy brain glutamate level: A mega-analysis of individual participant-level data. JAMA Psychiatry78(6): 667–681.
43.
MitchellAJVancampfortDSweersK, et al. (2013) Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders – A systematic review and meta-analysis. Schizophrenia Bulletin39(2): 306–318.
44.
ModinosGAllenPGraceAA, et al. (2015) Translating the MAM model of psychosis to humans. Trends in Neurosciences38(3): 129–138.
45.
ModinosGAllenPZugmanA, et al. (2020) Neural circuitry of novelty salience processing in psychosis risk: Association with clinical outcome. Schizophrenia Bulletin46(3): 670–679.
46.
ModinosGRichterAEgertonA, et al. (2021) Interactions between hippocampal activity and striatal dopamine in people at clinical high risk for psychosis: Relationship to adverse outcomes. Neuropsychopharmacology46(8): 1468–1474.
47.
MoghaddamBAdamsBVermaA, et al. (1997) Activation of glutamatergic neurotransmission by ketamine: A novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. The Journal of Neuroscience17(8): 2921–2927.
48.
NakaharaTTsugawaSNodaY, et al. (2021) Glutamatergic and GABAergic metabolite levels in schizophrenia-spectrum disorders: A meta-analysis of 1H-magnetic resonance spectroscopy studies. Molecular Psychiatry27: 744–757.
49.
NourMMLiuYArumuhamA, et al. (2021) Impaired neural replay of inferred relationships in schizophrenia. Cell184(16): 4315–4328.e17.
50.
O’DonnellTRotzingerSUlrichM, et al. (2003) Effects of chronic lithium and sodium valproate on concentrations of brain amino acids. European Neuropsychopharmacology13(4): 220–227.
51.
OlneyJWFarberNB (1995) Glutamate receptor dysfunction and schizophrenia. Archives of General Psychiatry52(12): 998–1007.
52.
OnwordiECWhitehurstTMansurA, et al. (2021) The relationship between synaptic density marker SV2A, glutamate and N-acetyl aspartate levels in healthy volunteers and schizophrenia: A multimodal PET and magnetic resonance spectroscopy brain imaging study. Translational Psychiatry11(1): 393.
53.
PillingerTBeckKGobjilaC, et al. (2017a) Impaired glucose homeostasis in first-episode schizophrenia: A systematic review and meta-analysis. JAMA Psychiatry74(3): 261–269.
54.
PillingerTBeckKStubbsB, et al. (2017b) Cholesterol and triglyceride levels in first-episode psychosis: Systematic review and meta-analysis. The British Journal of Psychiatry: The Journal of Mental Science211(6): 339–349.
55.
PilowskyLSBressanRAStoneJM, et al. (2006) First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients. Molecular Psychiatry11(2): 118–119.
56.
PrescotAPLocatelliAERenshawPF, et al. (2011) Neurochemical alterations in adolescent chronic marijuana smokers: A proton MRS study. NeuroImage57(1): 69–75.
57.
PretzschCMVoinescuBLythgoeD, et al. (2019) Effects of cannabidivarin (CBDV) on brain excitation and inhibition systems in adults with and without Autism Spectrum Disorder (ASD): A single dose trial during magnetic resonance spectroscopy. Translational Psychiatry9(1): 1–10.
58.
RowlandLMBustilloJRMullinsPG, et al. (2005) Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: A 4-T proton MRS study. The American Journal of Psychiatry162(2): 394–396.
59.
RubioMDDrummondJBMeador-WoodruffJH (2012) Glutamate receptor abnormalities in schizophrenia: Implications for innovative treatments. Biomolecules & Therapeutics20(1): 1–18.
60.
SanderCYSchoenbergerMHookerJM (2018) Response to comment on ‘In vivo [18F]GE-179 brain signal does not show NMDA-specific modulation with drug challenges in rodents and nonhuman primates’. ACS Chemical Neuroscience10(1): 773–775.
61.
Schizophrenia Working Group of the Psychiatric Genomics Consortium (2014) Biological insights from 108 schizophrenia-associated genetic loci. Nature511(7510): 421–427.
62.
SchoenbergerMSchroederFAPlaczekMS, et al. (2018) In vivo [18F]GE-179 brain signal does not show NMDA-specific modulation with drug challenges in rodents and nonhuman primates. ACS Chemical Neuroscience9(2): 298–305.
63.
SchwarzKMoessnangCSchweigerJI, et al. (2022) Ventral striatal–hippocampus coupling during reward processing as a stratification biomarker for psychotic disorders. Biological Psychiatry91(2): 216–225.
64.
SeldenNGeulaCHershL, et al. (1994) Human striatum: Chemoarchitecture of the caudate nucleus, putamen and ventral striatum in health and Alzheimer’s disease. Neuroscience60(3): 621–636.
65.
SimpsonEHKellendonkCKandelE (2010) A possible role for the striatum in the pathogenesis of the cognitive symptoms of schizophrenia. Neuron65: 585–596.
66.
SnyderJWilmanA (2010) Field strength dependence of PRESS timings for simultaneous detection of glutamate and glutamine from 1.5 to 7 T. Journal of Magnetic Resonance203(1): 66–72.
67.
StoneJMHowesODEgertonA, et al. (2010) Altered relationship between hippocampal glutamate levels and striatal dopamine function in subjects at ultra high risk of psychosis. Biological Psychiatry68(7): 599–602.
68.
StoneJMDietrichCEddenR, et al. (2012) Ketamine effects on brain GABA and glutamate levels with 1H-MRS: Relationship to ketamine-induced psychopathology. Molecular Psychiatry17(7): 664–665.
69.
StoneJMMorrisonPDPilowskyLS (2007) Glutamate and dopamine dysregulation in schizophrenia-a synthesis and selective review. Journal of Psychopharmacology21(4): 440–452.
70.
ÜstünTBRehmJChatterjiS, et al. (1999) Multiple-informant ranking of the disabling effects of different health conditions in 14 countries. The Lancet354(9173): 111–115.
71.
Van Den HeuvelMPMandiRCWStamCJ, et al. (2010) Aberrant frontal and temporal complex network structure in schizophrenia: A graph theoretical analysis. Journal of Neuroscience30(47): 15915–15926.
72.
Van SickleBJCoxASSchakK, et al. (2002) Chronic benzodiazepine administration alters hippocampal CA1 neuron excitability: NMDA receptor function and expression. Neuropharmacology43(4): 595–606.
73.
VibholmAKLandauAMAlstrupaAKO, et al. (2020) Activation of NMDA receptor ion channels by deep brain stimulation in the pig visualised with [18F]GE-179 PET. Brain Stimulation13(4): 1071–1078.
74.
VibholmAKLandauAMMøllerA, et al. (2021) NMDA receptor ion channel activation detected in vivo with [18F]GE-179 PET after electrical stimulation of rat hippocampus. Journal of Cerebral Blood Flow and Metabolism41(6): 1301–1312.
75.
VollenweiderFXVontobelPOye, et al. (2000) Effects of (S)-ketamine on striatal dopamine: A [11C]raclopride PET study of a model psychosis in humans. Journal of Psychiatric Research34(1): 35–43.
76.
Von ElmEAltmanDGEggerM, et al. (2008) The strengthening the reporting of observational studies in epidemiology (STROBE) statement: Guidelines for reporting observational studies. Journal of Clinical Epidemiology61(4): 344–349.
77.
VrajováMStastnýFHorácekJ, et al. (2010) Expression of the hippocampal NMDA receptor GluN1 subunit and its splicing isoforms in schizophrenia: Postmortem study. Neurochemical Research35(7): 994–1002.
78.
ZeiseMLKasparowSZieglgänsbergerW (1991) Valproate suppresses N-methyl-d-aspartate-evoked, transient depolarizations in the rat neocortex in vitro. Brain Research544(2): 345–348.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
